Oct 2, 2023 7:00 am EDT Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
Sep 25, 2023 7:00 am EDT Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Sep 19, 2023 7:00 am EDT Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
Sep 14, 2023 7:00 am EDT TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
Sep 12, 2023 7:00 am EDT Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
Sep 9, 2023 8:00 pm EDT Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
Sep 8, 2023 4:30 pm EDT TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
Sep 6, 2023 7:00 am EDT Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
Aug 7, 2023 7:00 am EDT New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
